If you live with sickle cell disease, you probably know the pain of a vaso-occlusive crisis: sudden, severe, and scary. But a new review says that for many adults, the pain itself changes as they get older. It shifts from those episodic crises to persistent, daily pain that's driven by years of tissue injury, damaged organs, and a nervous system that has become sensitized. That means the pain is no longer just about sickled cells blocking blood flow. It's also about worn-down joints, nerve damage, and ongoing inflammation, all made worse by kidney, liver, and heart problems that build up over time. The review doesn't report numbers or specific study details, but it makes a clear point: treating chronic pain in older adults with sickle cell requires a different approach. The authors call for a team-based, personalized plan that combines geriatric care with sickle cell expertise. The goal is simple: improve quality of life. But the review doesn't offer new data on which treatments work best, so questions remain about the safest and most effective options for this growing group of patients.
Chronic pain in aging adults with sickle cell disease shifts toward persistent, multifactorial syndromesSickle Cell Pain Changes With Age, Review Finds
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This narrative review explores the epidemiology, pathophysiology, and management of chronic pain specifically in the aging adult population with sickle cell disease. The review synthesizes how pain characteristics evolve over time in these patients.
Key findings indicate that pain shifts from episodic vaso-occlusive crises to persistent, multifactorial syndromes. These syndromes are driven by cumulative tissue injury, central sensitization, and progressive organ damage. The authors identify several contributors to this chronic pain, including musculoskeletal degeneration, neuropathic mechanisms, and chronic inflammation. These factors are further compounded by renal, hepatic, and cardiovascular dysfunction.
Clinical management requires a multidisciplinary, individualized approach that integrates both geriatric principles and sickle cell disease-specific considerations. This approach is considered critical for improving quality of life in this population. The review notes that the transition to chronic pain is a significant clinical shift for aging patients with sickle cell disease.
How this fits prior evidence
This narrative review addresses a gap in the management of chronic pain in aging adults with sickle cell disease. While prior coverage noted that opioid-free perioperative regimens are associated with lower pain scores and fewer side effects in hip arthroplasty, this review focuses on the specific transition from episodic to persistent pain in the sickle cell population. It also highlights the role of multi-factorial drivers like central sensitization and organ damage in chronic pain management.
Common questions
How does sickle cell pain change as people get older?
The review says pain shifts from sudden, episodic crises to persistent, daily pain. This chronic pain is driven by cumulative tissue injury, central sensitization, and progressive organ damage. It's no longer just about blocked blood flow; it involves worn joints, nerve damage, and inflammation.
What causes chronic pain in older adults with sickle cell disease?
According to the review, chronic pain comes from musculoskeletal degeneration, neuropathic mechanisms, and chronic inflammation. These are compounded by kidney, liver, and cardiovascular dysfunction that develop over time. So the pain is multifactorial, not just from sickled cells.
How should chronic pain be managed in aging adults with sickle cell disease?
The review recommends a multidisciplinary, individualized approach that integrates geriatric and sickle cell-specific principles. It doesn't specify which medications or treatments work best, so you should talk with your doctor about a plan tailored to your needs.
More on Sickle Cell Disease
View Original Abstract ↓
Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA
Dual antiplatelet therapy shows survival benefits for MINOCA patients
Related in Cardiology
From Other Specialties
